Selinexor Improves Late-Stage Treatment Options for Multiple Myeloma

Published: Wednesday, Sep 25, 2019
Sundar Jagannath, MBBS, director of the Multiple Myeloma Program, professor of medicine (hematology and medical oncology), of the Tisch Cancer Institute at Mount Sinai School of Medicine

Sundar Jagannath, MBBS

Treatment options for patients with multiple myeloma have expanded in recent years, leading to significantly better outcomes, but an unmet need has existed for patients with disease that is relapsed or refractory to multiple lines of therapy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication